Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL5210906

NC(=O)c1ccc2c(c1)NCC2.NCc1cccc(C(=O)N(CC(=O)O)c2ccccc2)c1.O=C(O)C(F)(F)F

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ACHE P22303 5/20 0.39
F2 P00734 3/20 0.34
ADRA2C P18825 1/20 0.33
PRSS1 P07477 1/20 0.33
PRSS2 P07478 1/20 0.33
PRSS3 P35030 1/20 0.33
KDM1A O60341 1/20 0.33
SLC6A4 P31645 1/20 0.33
OPRM1 P35372 5/20 0.33
OPRD1 P41143 5/20 0.33
NPY2R P49146 1/20 0.32
KLK1 P06870 1/20 0.32
HDAC11 Q96DB2 1/20 0.32
HDAC8 Q9BY41 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32
F11 P03951 1/20 0.32
KLKB1 P03952 1/20 0.32
F10 P00742 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL7423644 0.95 ACHE (0.39) ACHEF2ADRA2CPRSS1PRSS2
Trifluoroacetic Acid SCHEMBL5216054 0.94 ACHE (0.38) ACHEF2ADRA2CPRSS1PRSS2
Trifluoroacetic Acid SCHEMBL6486974 0.89 ACHE (0.38) ACHEADRA2COPRM1OPRD1F11
Trifluoroacetic Acid SCHEMBL5212837 0.89 ACHE (0.36) ACHEADRA2CHDAC11HDAC8HDAC6
Trifluoroacetic Acid SCHEMBL5213057 0.87 ACHE (0.34) ACHEF2HDAC11HDAC8HDAC6
Trifluoroacetic Acid SCHEMBL5212873 0.87 ACHE (0.34) ACHEF2HDAC11HDAC8HDAC6
Trifluoroacetic Acid SCHEMBL5210467 0.87 F2 (0.37) F2ADRA2CPRSS1PRSS2PRSS3
Trifluoroacetic Acid SCHEMBL7431702 0.86 NAMPT (0.34) ACHEHDAC11HDAC8HDAC6
Trifluoroacetic Acid SCHEMBL7428691 0.86 CFD (0.43) ACHEKDM1AHDAC8HDAC6KLKB1
Trifluoroacetic Acid SCHEMBL7424902 0.85 ACHE (0.34) ACHEF2HDAC11HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1240154-B1 SERINE PROTEASE INHIBITORS TULARIK LTD (GB) 2007-02-28 EP disclosed
US-7157585-B2 Serine protease inhibitors TULARIK LIMITED (GB) 2007-01-02 US disclosed
US-20050215587-A1 Serine protease inhibitors LIVELY SARAH E 2005-09-29 US disclosed
US-6916957-B2 Serine protease inhibitors TULARIK LIMITED (GB) 2005-07-12 US disclosed
US-20030018059-A1 Serine protease inhibitors PROTHERICS MOLECULAR DESIGN LIMITED (GB) 2003-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215587-A1 Serine protease inhibitors PRSS1, TPSAB1, CMA1 ACHE 480/4885F2 69/4885ADRA2C 2090/4885
US-20030018059-A1 Serine protease inhibitors TPSAB1, PRSS1, SERPINB1 ACHE 1165/4885F2 122/4885ADRA2C 2451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.